Literature DB >> 7863235

Helicobacter pylori phenotypes associated with peptic ulceration.

M J Blaser1.   

Abstract

Persistent infection with Helicobacter pylori occurs in a large percentage of the population, particularly in countries with low socioeconomic status. Such infection nearly always produces chronic gastric inflammation, although in most individuals it is clinically silent and only a minority of infected persons develop H. pylori-induced peptic ulcers. In this review, the hypothesis that diversity among H. pylori strains is at least partly responsible for the observed variability in the outcome of infection is explored. To date, four phenotypes that vary among H. pylori strains have been identified: variations in lipopolysaccharide structure; expression of the cagA-encoded product; production of a vacuolating cytotoxin, and enhanced activation of neutrophils. These phenotypes are associated with one another, with enhanced tissue inflammation, and with peptic ulceration, suggesting that H. pylori strain characteristics have an important influence on the clinical outcome of H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7863235

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  17 in total

1.  Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection.

Authors:  J Parsonnet; G D Friedman; N Orentreich; H Vogelman
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type.

Authors:  A Morgner; S Miehlke; M Stolte; A Neubauer; B Alpen; C Thiede; H Klann; F X Hierlmeier; C Ell; G Ehninger; E Bayerdörffer
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

3.  Helicobacter pylori non-cytotoxic genotype enhances mucosal gastrin and mast cell tryptase.

Authors:  D Basso; F Navaglia; L Brigato; F Di Mario; M Rugge; M Plebani
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

4.  Evaluation of the effects of strain-specific antigen variation on the accuracy of serologic diagnosis of Helicobacter pylori infection.

Authors:  Patrice A Marchildon; Toshiro Sugiyama; Yoshihiro Fukuda; Jeffrey S Peacock; Masahiro Asaka; Takashi Shimoyama; David Y Graham; Yoshihiro Fukada
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin.

Authors:  M Gerhard; N Lehn; N Neumayer; T Borén; R Rad; W Schepp; S Miehlke; M Classen; C Prinz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 6.  Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.

Authors:  A Markham; D McTavish
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  The antibody titers to Helicobacter pylori in 7 - 12 year old iron deficiency anemic children, in Ilam.

Authors:  Morteza Hoseinzadeh; Afra Khosravi; Koroush Sayemiri; Mohammad Hossein Rasoli; Alireza Mohaveri
Journal:  J Res Med Sci       Date:  2010-11       Impact factor: 1.852

8.  Lack of correlation between vacuolating cytotoxin activity, cagA gene in Helicobacter pylori, and peptic ulcer disease in children.

Authors:  M Loeb; P Jayaratne; N Jones; A Sihoe; P Sherman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

Review 9.  CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract.

Authors:  Ellen J Beswick; Victor E Reyes
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

10.  Helicobacter pylori cagA status and s and m alleles of vacA in isolates from individuals with a variety of H. pylori-associated gastric diseases.

Authors:  D G Evans; D M Queiroz; E N Mendes; D J Evans
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.